DUBLIN--(BUSINESS WIRE)--Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that it will be participating at the 13th Aegean Cornea Conference to be held in Crete. Vladimir Feingold, Presbia’s Chief Technology Officer and a Presbia board member, will be conducting a presentation about the Presbia Flexivue Microlens™, a proprietary optical lens implant that is an innovative solution for treating the loss of near-vision. The Aegean Cornea Conference, attended by world-wide leading anterior segment surgeons, will be held on July 1st through 3rd at Avra Imperial Hotel. Presbia is a sponsor of this Conference.
“This gathering of prominent surgeons from across the globe will further the awareness of our groundbreaking Microlens implant as a safe, effective, and easy to implement treatment for near-vision restoration that reduces the need for reading glasses,” said Todd Cooper, President and CEO of Presbia. “While we have approvals to commercialize our Microlens in dozens of countries worldwide, we’re taking a highly-focused approach in our commercialization strategy by continuing to lay the groundwork in Europe, predominately Germany, our next targeted area, and are underway in Asia-Pacific with an increasing presence in South Korea.”
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties, including, but not limited to, the factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.